Open Access Open Access  Restricted Access Subscription or Fee Access

Momordica: A Functional Food in Disease Prevention

Arpita Devi


Momordica is a genus of about 60 species. It is an annual or perennial climber belonging to the family Cucurbitaceae. It is a native of tropical and subtropical Africa, Asia and Australia. As far as the medicinal uses are concerned, Momordica has been used by the American natives for a long time as a treatment of diabetes; to prevent measles, hepatitis; to get rid of worms and parasites and the topical applications are used for healing wounds. It is in fact used in many parts of South America for a wide range of ailments such as malaria, measles, skin problems just to name a few. It is also used as an aphrodisiac and it is known for its anti-inflammatory effects. The young fruits are cooked and consumed in Asian countries as they are rich in carbohydrates, iron, vitamin A and C. In places like Jamaica, the leaves are used as a medicine for spasmodic pains of large intestine. This report compiles all the properties of Momordica.


Keywords: Momordica, diabetes, antitumor, apoptosis, abortifactant

Cite this Article

Devi A. Momordica: A functional food in disease prevention. Research and Reviews: Journal of Herbal Science. 2018; 7(2):

Full Text:



Sharma VN, Sogani RK, Arora RB and Bhargava K. Some observations on hypoglycaemic activity of Momordica charantia. Indian Journal of Medical Research, 1960, 48, 471-477.

Baldwa VS, Bhandari CM, Pangaria A and Goyal RK. Clinical trial in patients with diabetes mellitus of an insulin-like compound obtained from plant source. Ups J Med Sci. 1977, 82(1):39-41.

Vesely DL, Graves WR, Lo TM, Fletcher MA and Levey GS. Isolation of a guanylate cyclase inhibitor from the balsam pear (Momordica charantia abreviata). Biochemical and Biophysical Research Communications, 1977, Volume 77, Issue 4, 1294-1299.

Claflin AJ et al. Inhibition of growth and guanylate cyclase activity of an undifferentiated prostate adenocarcinoma by an extract of the balsam pear (Momordica charantia abbreviata). Proceedings of the National Academy of Sciences of the United States of America. 1978; 75(2):989-993.

Takemoto DJ, Kresie R, Vaughn D. Partial purification and characterization of a guanylate cyclase inhibitor with cytotoxic properties from the bitter melon (Momordica charantia), Biochemical and Biophysical Research Communications, Volume 94, Issue 1,1980, 332-339

Barbieri L, Lorenzoni E, Stirpe F. Inhibition of protein synthesis in vitro by a lectin from Momordica charantia and by other haemagglutinins. Biochemical Journal. 1979;182(2):633-635.

Barbieri L, Zamboni M, Lorenzoni E, Montanaro L, Sperti S and Stirpe F. Inhibition of protein synthesis in vitro by proteins from the seeds of Momordica charantia (bitter pear melon). Biochemical Journal, 1980, 186(2), 443-452.

Leatherdale BA, Panesar RK, Singh G, Atkins TW, Bailey CJ and Bignell AH. Improvement in glucose tolerance due to Momordica charantia (karela). Br Med J (Clin Res Ed), 1981, 282(6279), 1823-1824.

Welihinda J and Karunanayake EH. Extra-pancreatic effects of Momordica charantia in rats. Journal of Ethnopharmacology, 1986, 17.3, 247-255.

Takemoto DJ, Dunford C and McMurray MM. The cytotoxic and cytostatic effects of the bitter melon (Momordica charantia) on human lymphocytes. Toxicon, 1982, 20(3), 593-599.

Spreafico F, Malfiore C, Moras ML, Marmonti L, Filippeschi S, Barbieri L, Perocco P, and Stirpe F. The immunomodulatory activity of the plant proteins Momordica charantia inhibitor and pokeweed antiviral protein. International journal of immunopharmacology, 1983, 5, 335-343.

Aguwa CN and Mittal GC. Abortifacient effects of the roots of Momordica angustisepala. Journal of ethnopharmacology, 1983, 7.2, 169-173.

Ng TB, Wong CM, Li WW and Yeung HW. Peptides with antilipolytic and lipogenic activities from seeds of the bitter gourd Momordica charantia (family Cucurbitaceae). General Pharmacology: The Vascular System, 1987, 18(3), 275-281.

Saburo H, Makino J and Ikenaka T. Amino acid sequences and disulfide bridges of serine proteinase inhibitors from bitter gourd (Momordica charantia Linn.) seeds. Journal of biochemistry, 1989, 105.1, 88-92.

Huang SL et. al MAP 30: a new inhibitor of HIV-l infection and replication. FEBS, 1989, Volume 272, number 1,2, 12-18.

Budrat P and Shotipruk. A Extraction of Phenolic Compounds from Fruits of Bitter Melon (Momordica charantia ) with Subcritical Water Extraction and Antioxidant Activities of These Extracts. Chiang Mai J. Sci., 2008, 35(1) : 123-130

Yasuda M, Iwamoto M, Okabe H and Yamauchi T. A New Cucurbitane triterpenoid from Momordica charantia. Chem. Pharm. Bull. 1984, volume 32, issue 6, 2044-2049.

Chen JC, Lu L, Zhang XM, Zhou L, Li ZR and Qiu MH. Eight New Cucurbitane Glycosides, Kuguaglycosides A–H, from the Root of Momordica charantia L. Helvetica Chimica Acta, 2008, 91(5), 920-929.

Bendich A and Clements GC. A revision to the structural formation of vicine and its pyrimidine aglucone, divicine. Biochimica et Biophysica Acta, 1953

Lolitkar MM and Rao MRR. Note on a Hypoglycaemic Principle Isolated from the fruits of Momordica charantia. Journal of the University of Bombay, 1962, 29: 223–224.

Olaniyi AA. A neutral constituent of Momordica foetida. Lloydia, 1975, 38 (4): 361–362.

Scheele CW. On the essential salt of galls or gall-salt). Proceedings of the Royal Swedish Academy of Science, 1786, 7: 30–34.

Henri B. Observations on the preparation and purification of gallic acid, and on the existence of a new acid in galls, Annales de chimie et de physique, 1818, 9: 181–184.

Pelouze J. "Mémoire sur le tannin et les acides gallique, pyrogallique, ellagique et métagallique," Annales de chimie et de physique, 1833, 54: 337–365.

Kim SH et al. Gallic acid inhibits histamine release and pro-inflammatory cytokine production in mast cells. Toxicological Sciences, 2006, 91, no. 1, 123-131.

Kroes BH, Van den Berg AJJ, Van Ufford HQ, Van Dijk H and Labadie RP. Anti-inflammatory activity of gallic acid. Planta medica, 1992, 58(06), 499-504.

Hsieh CL, Lin CH, Chen KC, Peng CC and Peng RY. The Teratogenicity and the Action Mechanism of Gallic Acid Relating with Brain and Cervical Muscles. Ho Y-S, ed. PLoS ONE, 2015;10(6):e0119516.

Aruoma OI, Murcia A, Butler J and Halliwell B. Evaluation of the antioxidant and prooxidant actions of gallic acid and its derivatives. Journal of Agricultural and Food Chemistry, 1993, 41(11), 1880-1885.

Paolini A, Curti V, Pasi F, Mazzini G, Nano R and Capelli E. Gallic acid exerts a protective or an anti-proliferative effect on glioma T98G cells via dose-dependent epigenetic regulation mediated by miRNAs. International Journal of Oncology; 2015, 46(4):1491-1497.

Lee DK et al. Momordins inhibit both AP-1 function and cell proliferation. Anticancer Research, 1998, 18(1A):119-24

Matsuda H, Li Y and Yoshikawa M. Roles of capsaicin-sensitive sensory nerves, endogenous nitric oxide, sulfhydryls, and prostaglandins in gastroprotection by momordin Ic, an oleanolic acid oligoglycoside, on ethanol-induced gastric mucosal lesions in rats. Life sciences, 1999, 65.2, PL27-PL32.

Kim JH, Ju EM, Lee DK and Hwang HJ. Induction of apoptosis by momordin I in promyelocytic leukemia (HL-60) cells. Anticancer research, 2001, 22(3), 1885-1889.

Wang J, Yuan L, Xiao H, Xiao C, Wang Y and Liu X. Momordin Ic induces HepG2 cell apoptosis through MAPK and PI3K/Akt-mediated mitochondrial pathways. Apoptosis. 2013, 18(6):751-65.

Wang HY, Kan WC, Cheng TJ, Yu SH, Chang LH and Chuu JJ. Differential anti-diabetic effects and mechanism of action of charantin-rich extract of Taiwanese Momordica charantia between type 1 and type 2 diabetic mice. Food and Chemical Toxicology, 2014, 69, 347-356.

Tabata K, Hamano A, Akihisa T and Suzuki T Kuguaglycoside C. A constituent of Momordica charantia, induces caspase‐independent cell death of neuroblastoma cells. Cancer science, 2012, 103(12), 2153-2158.

Tan MJ, Ye JM, Turner N, Hohnen-Behrens C, Ke CQ, Tang CP, Chen T, Weiss HC, Gesing ER, Rowland A, James DE and Ye Y. Antidiabetic activities of triterpenoids isolated from bitter melon associated with activation of the AMPK pathway. Chem Biol. 2008, 15(3):263-73.

Yuki S, Itagaki S, Kurokawa T, Ogura J, Kobayashi M, Hirano T, Sugawara M and Iseki K. In vitro and in vivo antioxidant properties of chlorogenic acid and caffeic acid. International Journal of Pharmaceutics, 2011, 403, no. 1, 136-138.

Ohnishi M, Morishita H, Iwahashi H, Toda S, Shirataki Y, Kimura M and Kido R. Inhibitory effects of chlorogenic acids on linoleic acid peroxidation and haemolysis. phytochemistry, 1994, 36(3), 579-583.

Feng R, Lu Y, Bowman LL, Qian Y, Castranova V and Ding M. Inhibition of activator protein-1, NF-kappaB, and MAPKs and induction of phase 2 detoxifying enzyme activity by chlorogenic acid. J Biol Chem, 2005, 280(30):27888-95.

Lee WJ and Zhu BT. Inhibition of DNA methylation by caffeic acid and chlorogenic acid, two common catechol-containing coffee polyphenols. Carcinogenesis. 2006, 27(2):269-77.

Cho AS, Jeon SM, Kim MJ, Yeo J, Seo KI, Choi MS and Lee MK. Chlorogenic acid exhibits anti-obesity property and improves lipid metabolism in high-fat diet-induced-obese mice. Food Chem Toxicol. 2010, 48(3):937-43.

Joseph B and Jini D. Antidiabetic effects of Momordica charantia (bitter melon) and its medicinal potency. Asian Pacific Journal of Tropical Disease, 2013, 3(2):93-102.

Chaturvedi P. Antidiabetic potentials of Momordica charantia: multiple mechanisms behind the effects. J Med Food. 2012, 15(2):101-7.

Teoh SL, Latiff AA and Das S. The effect of topical extract of Momordica charantia (bitter gourd) on wound healing in nondiabetic rats and in rats with diabetes induced by streptozotocin. Clin Exp Dermatol. 2009, 34(7):815-22.

Fang EF, Zhang CZ, Fong WP and Ng TB. RNase MC2: a new Momordica charantia ribonuclease that induces apoptosis in breast cancer cells associated with activation of MAPKs and induction of caspase pathways. Apoptosis. 2012, 17(4):377-87.



Copyright (c) 2018 Research & Reviews: Journal of Herbal Science